Enhertu is a Intravenous Injection, Powder, Lyophilized, For Solution in the Human Prescription Drug category. It is labeled and distributed by Daiichi Sankyo, Inc.. The primary component is Trastuzumab Deruxtecan.
| Product ID | 65597-406_2941ff87-6750-4d3f-b2d5-431dc740ebb9 |
| NDC | 65597-406 |
| Product Type | Human Prescription Drug |
| Proprietary Name | Enhertu |
| Generic Name | Fam-trastuzumab Deruxtecan-nxki |
| Dosage Form | Injection, Powder, Lyophilized, For Solution |
| Route of Administration | INTRAVENOUS |
| Marketing Start Date | 2019-12-20 |
| Marketing Category | BLA / BLA |
| Application Number | BLA761139 |
| Labeler Name | Daiichi Sankyo, Inc. |
| Substance Name | TRASTUZUMAB DERUXTECAN |
| Active Ingredient Strength | 100 mg/5mL |
| NDC Exclude Flag | N |
| Listing Certified Through | 2023-12-31 |
| Marketing Start Date | 2019-12-20 |
| NDC Exclude Flag | N |
| Sample Package? | N |
| Marketing Category | BLA |
| Application Number | BLA761139 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Billing Unit | EA |
| Marketing Start Date | 2019-12-20 |
| Ingredient | Strength |
|---|---|
| TRASTUZUMAB DERUXTECAN | 100 mg/5mL |
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
![]() ENHERTU 87675518 5640578 Live/Registered |
DAIICHI SANKYO COMPANY, LIMITED 2017-11-07 |